[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.238.190.122. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 166
Citations 0
Comment & Response
April 9, 2020

Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma—Reply

Author Affiliations
  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
JAMA Oncol. Published online April 9, 2020. doi:10.1001/jamaoncol.2020.0343

In Reply We thank Yang and colleagues for their interest and appreciation of our phase 2 trial.1 In their letter, they address the significant improvement in overall survival (OS) with the combination of regional hepatic arterial infusion (HAI) therapy plus systemic gemcitabine and oxaliplatin. In particular, they note the larger difference between the median progression-free survival (PFS) (11.8 months) and median OS (25.0 months) achieved with this combination in our study compared with that achieved with systemic gemcitabine and cisplatin alone in the Advanced Biliary Tract Cancer (ABC) trials (difference between median PFS and OS, 7.0 months).2 In our study, patients received a median of 5 cycles (range, 1-25) of HAI floxuridine and 21 cycles (range, 5-36) of gemcitabine on protocol, and we hypothesize that early and adequate treatment of the primary liver tumor led to longer survival owing to preservation of liver function even in the setting of metastatic disease. This is further supported by a second study of locoregional therapy with radioembolization demonstrating a similar difference in PFS and OS.3

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×